| http://purl.uniprot.org/citations/18288441 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/18288441 | http://www.w3.org/2000/01/rdf-schema#comment | "The effects of the non-peptide vasopressin V(2) receptor antagonist 5-dimethylamino-1-[4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine hydrochloride (OPC-31260) on the cerebral oedema induced by general cerebral hypoxia were studied in rats. The general cerebral hypoxia was produced by bilateral common carotid ligation in Sprague-Dawley rats of the CFY strain. By 6 h after the ligation, half of the rats had died, but the survival rate was significantly higher following OPC-31260 administration. Electron microscopic examinations revealed typical ischaemic changes after the carotid ligation. The carotid ligation increased the brain contents of water and Na(+) and enhanced the plasma vasopressin level. The increased brain water and Na(+) accumulation was prevented by OPC-31260 administration, but the plasma vasopressin level was further enhanced by OPC-31260. These results demonstrate the important role of vasopressin in the development of the disturbances in brain water and electrolyte balance in response to general cerebral hypoxia. The carotid ligation-induced cerebral oedema was significantly reduced following oral OPC-31260 administration. The protective mechanism exerted by OPC-31260 stems from its influence on the renal vasopressin V(2) receptors. These observations might suggest an effective approach to the treatment of global hypoxia-induced cerebral oedema in humans."xsd:string |
| http://purl.uniprot.org/citations/18288441 | http://purl.org/dc/terms/identifier | "doi:10.1007/s00701-007-1400-1"xsd:string |
| http://purl.uniprot.org/citations/18288441 | http://purl.uniprot.org/core/author | "Varga C."xsd:string |
| http://purl.uniprot.org/citations/18288441 | http://purl.uniprot.org/core/author | "Parducz A."xsd:string |
| http://purl.uniprot.org/citations/18288441 | http://purl.uniprot.org/core/author | "Laszlo F."xsd:string |
| http://purl.uniprot.org/citations/18288441 | http://purl.uniprot.org/core/author | "Laszlo F.A."xsd:string |
| http://purl.uniprot.org/citations/18288441 | http://purl.uniprot.org/core/author | "Molnar A.H."xsd:string |
| http://purl.uniprot.org/citations/18288441 | http://purl.uniprot.org/core/author | "Berko A."xsd:string |
| http://purl.uniprot.org/citations/18288441 | http://purl.uniprot.org/core/author | "Rojik I."xsd:string |
| http://purl.uniprot.org/citations/18288441 | http://purl.uniprot.org/core/date | "2008"xsd:gYear |
| http://purl.uniprot.org/citations/18288441 | http://purl.uniprot.org/core/name | "Acta Neurochir (Wien)"xsd:string |
| http://purl.uniprot.org/citations/18288441 | http://purl.uniprot.org/core/pages | "265-271"xsd:string |
| http://purl.uniprot.org/citations/18288441 | http://purl.uniprot.org/core/title | "Inhibitory effect of vasopressin receptor antagonist OPC-31260 on experimental brain oedema induced by global cerebral ischaemia."xsd:string |
| http://purl.uniprot.org/citations/18288441 | http://purl.uniprot.org/core/volume | "150"xsd:string |
| http://purl.uniprot.org/citations/18288441 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/18288441 |
| http://purl.uniprot.org/citations/18288441 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/18288441 |
| http://purl.uniprot.org/uniprot/#_P30518-mappedCitation-18288441 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/18288441 |
| http://purl.uniprot.org/uniprot/#_Q16271-mappedCitation-18288441 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/18288441 |
| http://purl.uniprot.org/uniprot/P30518 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/18288441 |
| http://purl.uniprot.org/uniprot/Q16271 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/18288441 |